The Imugene Limited (ASX: IMU) share price is marching higher in early trade. Imugene shares are up 4% even as the All Ordinaries Index (ASX: XAO) tumbles 1%.
The Imugene share price closed yesterday at 25 cents and is currently trading at 26 cents.
Below we look at the immuno-oncology company’s clinical trial collaboration announcement.
What collaboration was announced?
The Imugene share price is gaining after the company reported that it’s entered into a new clinical trial collaboration and supply agreement with US pharmaceutical giant Merck & Co. Inc. (NYSE: MRK), under its tradename MSD.
The collaborative trial will treat patients with HER-2 positive gastric cancer with Imugene’s HER-Vaxx, combined with MSD’s pembrolizumab. The trial will evaluate both the safety and efficacy of the combined treatment approach.
Commenting on the collaboration, Leslie Chong, Imugene’s CEO, said:
HER-Vaxx has already shown a tolerable safety profile and encouraging efficacy in patients with metastatic HER-2 positive gastric cancer, and we look forward to further evaluating HER-Vaxx with pembrolizumab in a relapsed/refractory metastatic setting.
This collaboration with MSD is significant for our company as it provides the opportunity to optimize and enhance our formulations and utility in an additional setting in an effort to improve outcomes for more patients.
Imugene said the main goal of the study is to evaluate the safety and response rate of the combination therapy. It will also assess patients’ “duration of response, progression free survival, overall survival, and biomarker evaluation”.
In accordance with the agreement, Imugene will sponsor and fund the clinical study. It said this will be done from its existing budgets and resources.
In return, MSD will provide pembrolizumab for the duration of the study, which is expected to run for at least 24 months.
Imugene share price snapshot
The Imugene share price has been a stellar performer over the past 12 months, up 112%. By comparison, the All Ordinaries has gained 5% over that same time.
The post Imugene (ASX:IMU) share price lifts on major collaboration announcement appeared first on The Motley Fool Australia.
Should you invest $1,000 in Imugene right now?
Before you consider Imugene, you’ll want to hear this.
Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Imugene wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.
*Returns as of January 13th 2022
More reading
The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.
from The Motley Fool Australia https://ift.tt/OfP1jKr
Leave a Reply